Trials / Withdrawn
WithdrawnNCT02780882
SOM230 Ectopic ACTH-producing Tumors
A Proof of Concept and Open-label Study to Test the Efficacy and Safety of Pasireotide in Patients With Ectopic ACTH-producing Tumors
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Cedars-Sinai Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this prospective open-label phase II study, is to evaluate the efficacy of pasireotide twice daily subcutaneous injections for normalizing 24 hour urine free cortisol in patients with ectopic ACTH-producing tumors as measured by the proportion of patients achieving normal UFC at the end of the study period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pasireotide |
Timeline
- Start date
- 2015-12-01
- Primary completion
- 2018-12-01
- Completion
- 2019-06-01
- First posted
- 2016-05-24
- Last updated
- 2018-01-26
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02780882. Inclusion in this directory is not an endorsement.